Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

OSU-2S, a Novel PKC Activator, Mediates PKC Dependent Cell Death, Differentiation and Cell Cycle Arrest in Acute Myeloid Leukemia

Swagata Goswami, MS, Rajeswaran Mani, DVM,PhD, Xiaokui Mo, PhD MAS, Pearlly S. Yan, PhD, Michael B Broe, PhD, Ralf Bundschuh, PhD, Larry State Beaver, Kevan Zapolnik, BS, Zhiliang Xie, Donna Bucci, David M. Lucas, PhD, Allison R. Walker, MD MPH, Alice S. Mims, MD MSCR, Rebecca B. Klisovic, MD, Ching-Shih Chen, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Sumithira Vasu, MDMBBS, Natarajan Muthusamy, DVM,PhD

Blood (2017) 130 (Supplement 1): 1247.

https://doi.org/10.1182/blood.V130.Suppl_1.1247.1247

Published: 2017

Journal Articles

CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia

Swagata Goswami, MS, Rajeswaran Mani, DVM PhD, Chi-Ling Chiang, MS, Frank W Frissora, M.S., Xiaokui Mo, PhD MAS, Zhiliang Xie, Donna Bucci, Amber Gordon, MLS, David M. Lucas, PhD, William Blum, MD, Alison R. Walker, MD MPH, Alice S. Mims, MD MSCR, Rebecca B Klisovic, MD, Ching-Shih Chen, PhD, Robert J Lee, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Sumithira Vasu, MBBS, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 2748.

https://doi.org/10.1182/blood.V128.22.2748.2748

Published: 2016

Journal Articles

BRAF V600E Induces ABCB1/P-Glycoprotein Expression and Drug Resistance in B-Cells Via AP-1 Activation

Yo-Ting Tsai, MS, Gerard Lozanski, MD, Amy M. Lehman, MAS, Ellen Sass, Erin K. Hertlein, PhD, Santosh Salunke, Ching-Shih Chen, PhD, Michael R. Grever, MD, John C. Byrd, MD, David M. Lucas, PhD

Blood (2015) 126 (23): 2477.

https://doi.org/10.1182/blood.V126.23.2477.2477

Published: 2015

Journal Articles

Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia

Rajeswaran Mani, DVM, Yicheng Mao, PhD, Frank W Frissora, M.S., Chi-ling Chiang, Jiang Wang, Yuan Zhao, Yun Wu, Bo Yu, Ph.D., Ribai Yan, Xiaokui Mo, PhD, Sivasubramanian Baskar, PhD, Christoph Rader, Ph.D., Mitch A. Phelps, PhD, Robert J. Lee, Ph.D, Ching-Shih Chen, PhD, James Lee, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D

Blood (2013) 122 (21): 4168.

https://doi.org/10.1182/blood.V122.21.4168.4168

Published: 2013

Journal Articles

Increased Expression Of IL-15 Promotes Cutaneous T-Cell Lymphomagenesis Via The Upregulation Of Histone Deacetylases: Evidence For Successful Preclinical Targeting

Anjali Mishra, Ph.D., Krista M.D. La Perle, DVM, PhD, Dipl. ACVP, Laura Sullivan, BS, Gregory H Sams, Douglas P Curphey, Kathleen McConnell, BS, Jun Qi, PhD, Henry K Wong, MD, PhD, Samuel K Kulp, PhD, Soledad Fernandez, PhD, James E Bradner, MD, Guido Marcucci, MD, Ching-Shih Chen, PhD, Pierluigi Porcu, MD, Michael A. Caligiuri, MD

Blood (2013) 122 (21): 1826.

https://doi.org/10.1182/blood.V122.21.1826.1826

Published: 2013

Journal Articles

OSU-T315, An Integrin-Linked Kinase (ILK) Inhibitor, Induces Apoptosis By Targeting B Cell Receptor and CD49d Mediated AKT/ERK Activation In Chronic Lymphocytic Leukemia Cells

Ta-Ming Liu, YongHua Ling, Mitch A. Phelps, PhD, Jennifer A. Woyach, MD, Erin K Hertlein, PhD, William H. Towns, Jessica MacMurray, Santosh B. Salunke, PhD, Ching-Shih Chen, PhD, John C. Byrd, MD, Amy J. Johnson, PhD

Blood (2013) 122 (21): 2523.

https://doi.org/10.1182/blood.V122.21.2523.2523

Published: 2013

Journal Articles

PKC Inhibitor AEB071 Demonstrates Pre-Clinical Activity In Chronic Lymphocytic Leukemia

Dalia ElGamal, PhD, Yiming Zhong, PhD, Katie Williams, MS, Chia-Hsien Wu, Ching-Shih Chen, PhD, Rosa Lapalombella, PhD, John C. Byrd, MD

Blood (2013) 122 (21): 4187.

https://doi.org/10.1182/blood.V122.21.4187.4187

Published: 2013

Journal Articles

FTY720 Demonstrates Promising in-Vitro and in-Vivo Pre-Clinical Activity by Down-Modulation of Cyclin D1 and Pakt in Mantle Cell Lymphoma.

Lapo Alinari, MD, Qing Liu, PhD, Ching-Shih Chen, PhD, Fengting Yan, MD, PhD, James T Dalton, PhD, Rosa Lapalombella, PhD, Xiaoli Zhang, PhD, Teresa Lin, BS, John C. Byrd, MD, Robert A. Baiocchi, MD, PhD, Natarajan Muthusamy, PhD

Blood (2009) 114 (22): 3728.

https://doi.org/10.1182/blood.V114.22.3728.3728

Published: 2009

Journal Articles

The Novel Histone Deacetylase Inhibitor OSU-HDAC42 Has Class I and II Histone Deacetylase (HDAC) Inhibitory Activity and Represents a Novel Therapy for Chronic Lymphocytic Leukemia.

Derek A. West, BS, David M. Lucas, PhD, Melanie E. Davis, PhD, Michael D. De Lay, BA, Amy J. Johnson, PhD, Sara E. Guster, MS/MBA, Michael A. Freitas, PhD, Mark R. Parthun, PhD, Dasheng Wang, PhD, Samuel K. Kulp, PhD/DVM, Michael R. Grever, MD, Ching-Shih Chen, PhD, John C. Byrd, MD

Blood (2006) 108 (11): 2807.

https://doi.org/10.1182/blood.V108.11.2807.2807

Published: 2006

Journal Articles

Characterization of HDACI OSU42 as a Novel Histone Deacetylase Inhibitor in AML Cell Lines.

Jin Sun, PhD, Shujun Liu, PhD, Jianhua Yu, PhD, Min Wei, BS, Charlene Mao, PhD, Haiming Ding, PhD, Jessica Kearney, BS, LeNguyen Huynh, MS, Peter Paschka, MD, Dachun Wang, PhD, Rebecca B. Klisovic, MD, Danilo Perrotti, PhD, Ching-shih Chen, PhD, Williom George Blum, MD, Guido Marcucci, MD

Blood (2006) 108 (11): 1988.

https://doi.org/10.1182/blood.V108.11.1988.1988

Published: 2006

Journal Articles

OSU03012, a Novel Celecoxib Derivative, Induces Apoptosis in Multiple Myeloma Cells Independently of Caspase Activation.

Shuhong Zhang, PhD, Valerie L. White, Amy Johnson, PhD, Ching-Shih Chen, PhD, Sherif S. Farag, MD, PhD

Blood (2006) 108 (11): 5075.

https://doi.org/10.1182/blood.V108.11.5075.5075

Published: 2006

Journal Articles

OSU-HDAC42, a Novel Histone Deacetylase Inhibitor, Induces Apoptosis in a Caspase-Dependent Manner and Induces p 21WAF1/CIP1 and p16 Expression in Multiple Myeloma Cell Lines.

Valerie L. White, Shuhong Zhang, PhD, David Lucas, PhD, Ching-Shih Chen, PhD, Sherif S. Farag, MD, PhD

Blood (2006) 108 (11): 5078.

https://doi.org/10.1182/blood.V108.11.5078.5078

Published: 2006

Journal Articles

The TCL-1 Transgenic Mouse Is an Effective Tool for Pre-Clinical Drug Development in Chronic Lymphocytic Leukemia.

Amy J. Johnson, PhD, Ryan Edwards, BA, Lisa L. Smith, MS, David M. Lucas, PhD, Carlo M. Croce, MD, Natarajan Muthusamy, DVM, PhD, Ching-Shih Chen, PhD, Zhongfa Liu, PhD, Kenneth Chan, PhD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2005) 106 (11): 51.

https://doi.org/10.1182/blood.V106.11.51.51

Published: 2005

Journal Articles

A Novel Celecoxib Derivative, OSU03012, Induces Cytotoxicity in Primary CLL Cells and Transformed B-Cell Lymphoma Via a Caspase and Bcl-2 Independent Mechanism.

Amy Johnson, PhD, Lisa Smith, Jiuxiang Zhu, Nyla Heerema, PhD, Sara Guster, Andrew Mone, MD, PhD, Michael Grever, MD, Ching-Shih Chen, PhD, John Byrd, MD

Blood (2004) 104 (11): 3471.

https://doi.org/10.1182/blood.V104.11.3471.3471

Published: 2004

NARROW

OSU-2S, a Novel PKC Activator, Mediates PKC Dependent Cell Death, Differentiation and Cell Cycle Arrest in Acute Myeloid Leukemia

CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia

BRAF V600E Induces ABCB1/P-Glycoprotein Expression and Drug Resistance in B-Cells Via AP-1 Activation

Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia

Increased Expression Of IL-15 Promotes Cutaneous T-Cell Lymphomagenesis Via The Upregulation Of Histone Deacetylases: Evidence For Successful Preclinical Targeting

OSU-T315, An Integrin-Linked Kinase (ILK) Inhibitor, Induces Apoptosis By Targeting B Cell Receptor and CD49d Mediated AKT/ERK Activation In Chronic Lymphocytic Leukemia Cells

PKC Inhibitor AEB071 Demonstrates Pre-Clinical Activity In Chronic Lymphocytic Leukemia

FTY720 Demonstrates Promising in-Vitro and in-Vivo Pre-Clinical Activity by Down-Modulation of Cyclin D1 and Pakt in Mantle Cell Lymphoma.

The Novel Histone Deacetylase Inhibitor OSU-HDAC42 Has Class I and II Histone Deacetylase (HDAC) Inhibitory Activity and Represents a Novel Therapy for Chronic Lymphocytic Leukemia.

Characterization of HDACI OSU42 as a Novel Histone Deacetylase Inhibitor in AML Cell Lines.

OSU03012, a Novel Celecoxib Derivative, Induces Apoptosis in Multiple Myeloma Cells Independently of Caspase Activation.

OSU-HDAC42, a Novel Histone Deacetylase Inhibitor, Induces Apoptosis in a Caspase-Dependent Manner and Induces p 21WAF1/CIP1 and p16 Expression in Multiple Myeloma Cell Lines.

The TCL-1 Transgenic Mouse Is an Effective Tool for Pre-Clinical Drug Development in Chronic Lymphocytic Leukemia.

A Novel Celecoxib Derivative, OSU03012, Induces Cytotoxicity in Primary CLL Cells and Transformed B-Cell Lymphoma Via a Caspase and Bcl-2 Independent Mechanism.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only